Does Atazanavir And Cobicistat Interact with Repaglinide?
CDI records a major classification for Atazanavir And Cobicistat and Repaglinide. The stored summary is: Repaglinide is highly dependent on CYP2C8 for clearance with narrow therapeutic index. EVOTAZ use is not recommended with repaglinide due to potential for increased plasma concentrations. The mechanism involves cyp2c8 inhibition by atazanavir. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
Evidence status
A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.
Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.
Saved label reference on DailyMed. This identifier has not been checked here as support for the current claim.
- Stored CDI classification
- Major
- Atazanavir And Cobicistat Class
- Cytochrome P450 3A Inhibitor
- Repaglinide Class
- Glinide
- Management
- Confirm exact products with your pharmacist
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP2C8 inhibition by atazanavir
What To Tell Your Doctor or Pharmacist
If you are taking Atazanavir And Cobicistat and your doctor is considering prescribing Repaglinide (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider